Skip to content
drillr.ai

PFE

Pfizer Inc.

NYSE · USHealthcareDrug Manufacturers - General
$24.75-1.20%

Price as of Jul 20, 2026

PFE news

Pfizer Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

    U.S. FDA Approves PADCEV(®) plus Keytruda(®) as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility * First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care * Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus st

    Business Wire ·

  2. Pfizer Declares Third-Quarter 2026 Dividend

    Pfizer Declares Third-Quarter 2026 Dividend Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026. Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy.

    Business Wire ·

  3. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

    FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance * First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status * Approval based on data from the collaborative Phase 3 PATINA trial, which showed a 24% risk reduction in disease progression for IBRANCE added to anti-HER2 and endocrine therapies * Continues decade-long legacy of IBRANCE helping transform the treatment for HR+ metastatic breast cancer Pfizer

    Business Wire ·

  4. Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small

    Business Wire ·

  5. Pfizer Announces Chief Financial Officer Transition

    Pfizer Announces Chief Financial Officer Transition Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfi

    Business Wire ·

  6. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

    U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need * Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors * HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B ages 6 to 11 years old Pfizer Inc. (NYSE: PFE) today announ

    Business Wire ·

  7. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.

    Business Wire ·

  8. Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

    Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer * Cohort 3 analysis from the Phase 3 BREAKWATER study showed a 56% reduction in the risk of disease progression or death compared to traditional chemotherapy regimen * Overall survival benefit was also observed, with a 44% reduction in the risk of death * BRAFTOVI in combination with cetuximab and fluorouracil-based chemotherapy is the only approved targeted regimen for BRAF V600E-mut

    Business Wire ·

  9. TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

    TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer * First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations * There was an estimated 77% probability of remaining progression-free at three years with TALZENNA plus XTANDI * Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and p

    Business Wire ·

  10. Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

    Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines PR Newswire SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new

    PR Newswire ·

  11. Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

    Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities acro

    Business Wire ·

  12. Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors (https://cts.businesswire.com/ct/CT?id=smart

    Business Wire ·

  13. Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

    Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results * Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric population * An oral presentation at ISPPD highlighted an approximately 9 to 15-fold higher serotype 3 immunogenicity response after Dose 3 and 4 in infants receiving Pfi

    Business Wire ·

  14. Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

    Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 PR Newswire TOKYO, May 18, 2026 10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncol

    PR Newswire ·

  15. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

    European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors * Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy, with continued benefit observed in open-label extension study * HYMPAVZI is the only once-weekly subcutaneous treatment approved in the EU for both people living with hemophilia A or B, with or without inhibitors Pfizer Inc. (NYSE: PFE) tod

    Business Wire ·

  16. For the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus

    For the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus PR Newswire JAKARTA, Indonesia, May 7, 2026 JAKARTA, Indonesia, May 7, 2026 /PRNewswire/ -- In conjunction with World Immunization Week, Pfizer Indonesia, together with healthcare professionals has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out simultaneously across Indonesia, Malaysia, Singapore and the Philippines, the campaign b

    PR Newswire ·

  17. For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health

    For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health PR Newswire MAKATI CITY, Philippines, April 30, 2026 MAKATI CITY, Philippines, April 30, 2026 /PRNewswire/ -- Pfizer Philippines, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out across the Philippines, Malaysia, Indonesia and Singapore, the campaign brings together medical exp

    PR Newswire ·

  18. Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

    Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma * Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survival * Safety was consistent with the known ELREXFIO profile, with no new safety signals identified * Trial remains ongoing to assess overall survival, a key secondary endpoi

    Business Wire ·

  19. Pfizer Reaches Three Settlement Agreements for VYNDAMAX

    Pfizer Reaches Three Settlement Agreements for VYNDAMAX Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX(®) (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.S. paten

    Business Wire ·

  20. Pfizer Declares Second-Quarter 2026 Dividend

    Pfizer Declares Second-Quarter 2026 Dividend Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company’s common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026. The second-quarter 2026 cash dividend will be the 350th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs

    Business Wire ·